FC2Video

www.taipanfinancialnews.com -- Big pharma has a hit a brick wall. Hundreds of patents are set to expire leaving drug companies with limit revenue streams and no new treatments on the horizon. Now they're turning to small bio-techs on the cusp of cutting edge treatments. Here's why these small drug companies offer short and long term gains.

If the integrated link within the video doesn't work on this viewer, click on this link or paste it into your browser:
http://www.isecureonline.com/reports/TAI/WTAIH308/